Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 40.4258
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 963348484992.0
- FreeCF/Share 10.0576
- PFCF 106.7931
- PE 52.2408
- Debt/Assets 0.3698
- DivYield 0.0056
- ROE 1.0226
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
News
Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs
Published: October 30, 2025 by: Investopedia
Sentiment: Positive
Strong sales of Eli Lilly's weight-loss treatments Mounjaro and Zepbound helped power strong quarterly earnings, and the drugmaker boosted its outlook.
Read More
Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand
Published: October 30, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) on Thursday reported third quarter 2025 financial results that handily beat Wall Street forecasts, as the company continued to see strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro. The pharmaceutical giant's revenue for the quarter rose 54% year over year to $17.60 billion, surpassing the analyst consensus estimate of $16.01 billion, according to data provided by LSEG.
Read More
Eli Lilly Blows Away Q3 Earnings Expectations
Published: October 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance.
Read More
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
Published: October 29, 2025 by: CNBC
Sentiment: Positive
Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time. Starting in mid-November, cash-paying patients with a prescription can purchase single-dose vials of Zepbound at discounts of 50% or more through the retailer's nearly 4,600 pharmacy locations or via home delivery.
Read More
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
Read More
Lilly and Walmart launch first retail pick-up option for weight-loss drug
Published: October 29, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Walmart said on Wednesday they are partnering to expand access to single-dose vials of Lilly's weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
Read More
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials Strategic collaboration marks the first time patients using LillyDirect, Lilly's direct-to-consumer healthcare platform, can access self-pay pricing for Zepbound vials at a retail pharmacy location LillyDirect pick-up option at Walmart offers millions of Americans living with obesity additional convenience, access and choice in how they get their medication INDIANAPOLIS , Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Walmart Inc. (NYSE: WMT) today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials …
Read More
1 Undervalued Growth Stock Down 8% to Buy Before 2026
Published: October 28, 2025 by: The Motley Fool
Sentiment: Positive
Eli Lilly's performance over the past year hasn't been as strong as usual. The company's growth prospects justify its higher-than-average valuation.
Read More
Lilly partners with Nvidia on AI supercomputer to speed up drug development
Published: October 28, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten development cycles, getting medicines to people faster.
Read More
Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly and Nvidia are partnering to build what the companies call the pharmaceutical industry's "most powerful" supercomputer and so-called AI factory to help accelerate drug discovery and development across the broader sector. It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to shorten the time it takes to bring cures to patients, while reducing costs at every stage of the drug discovery and development process.
Read More
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
New AI capabilities will help scientists identify, optimize and validate new molecules Additional applications include manufacturing, medical imaging and enterprise AI agents INDIANAPOLIS , Oct. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA. The supercomputer will power an "AI factory," a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.
Read More
Eli Lilly Partners With Nvidia to Build AI Supercomputer for Drug Discovery
Published: October 28, 2025 by: WSJ
Sentiment: Positive
The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Read More
Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Lilly declares fourth-quarter 2025 dividend
Published: October 27, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
Read More
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Published: October 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Read More
Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Read More
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Read More
Eli Lilly: Time To Buy LLY Stock?
Published: October 24, 2025 by: Forbes
Sentiment: Positive
Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, orforglipron, specifically for diabetes management and weight loss.
Read More
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Read More
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Eli Lilly Q3 earnings eyed for insights into drug pricing policies, obesity and diabetes drug performance
Published: October 20, 2025 by: Proactive Investors
Sentiment: Neutral
Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affecting margins and growth.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Read More
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Published: October 17, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Read More
Is Trump Going to Kill the GLP-1 Cash Cow?
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
Read More
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Published: October 17, 2025 by: Benzinga
Sentiment: Negative
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000